rectal carcinoma
DESCRIPTION
RECTAL CARCINOMA. ELSHAMI ELAMIN, MD Central Care Cancer Center Newton, KS-USA. RISK FACTORS. Dietary factors Fat ? Fiber ? Calcium ? Vitamins (E, -carotene) Aspirin/NSAIDs (Cox inhibitors) Sulindac reduces polyps in FAP pts Aspirin lower risk of CRC. RISK FACTORS. - PowerPoint PPT PresentationTRANSCRIPT
1
RECTAL CARCINOMARECTAL CARCINOMA
ELSHAMI ELAMIN, MD
Central Care Cancer Center
Newton, KS-USA
NextPrevious
2
RISK FACTORSRISK FACTORS
Dietary factors• Fat• ? Fiber• ? Calcium• ? Vitamins (E, -carotene)
Aspirin/NSAIDs (Cox inhibitors)• Sulindac reduces polyps in FAP pts• Aspirin lower risk of CRC
NextPrevious
3
RISK FACTORSRISK FACTORS
Genetic Factors– FAP(APC gene = Tumor suppressor gene)
• 1-2% of CRC• Invasive cancer occurs at ~ 42Y
– HNPCC (MMR mutations)• Hx of > 3 family members involving 2
generations with one diagnosed before age 50• 4-6% incidence• Rt-sided cancer• Caused by defective DNA mismatch repair genes
NextPrevious
4
Steps for Colorectal CarcinogenesisSteps for Colorectal Carcinogenesis
1- Mutation at MCC and APC genes
2- K-ras oncogene activates adenoma to carcinoma
3- Mutation of p53 tumor suppressor gene
NextPrevious
5
SCREENINGSCREENINGPatients with average risk
• Asymptomatic• >50Y• No colorectal risk factors
FOBT (33% reduction in mortality)Flexible sig (60-80% reduction in mortality)Double-contrast BEColonoscopy (Gold standard)
NextPrevious
6
Patients with increased RiskPatients with increased Risk
First-degree relative with CRC or adenomatous polyps
FAPF.H. of HNPCCAdenomatous polypsCRCIBD
NextPrevious
7
Hereditary CRC syndromesHereditary CRC syndromesScreening and ManagementScreening and Management
FAP– Genetic counseling/gene testing
• Is cost-effective
– Genetic mutation not identified:• Flex sig at puberty and annualy
• Colonoscopy if +ve sig
– +ve FAP• Total colectomy
NextPrevious
8
HNPCC (Lynch syndrome)HNPCC (Lynch syndrome)
Lynch I:– No associated cancers
Lynch II:– Associated with ovarian, uterine cancers
Genetic testing– Difficult due to multiple mutations
• MLH1, MSH2 mutations
Screening begin at 20Y and every 1-2YGenetically +ve: Consider colectomy/TAH/BSO
NextPrevious
9
Work-upWork-upLaboratory:
– LFTs– CBC, Iron profile– CEA
Preoperative CT scan– Colon cancer: Adjacent organ invasion/Liver met– Rectal: Adjacent organ invasion/LN spread
• For preop RT
NextPrevious
10
MRIMRI
Bowel wall penetration– MRI: 64%, CT: 62%
Sensitivity for LN met: 15-40%Endorectal surface coil MRI for N1
– 72% specificity
NextPrevious
11
Transrectal USTransrectal US
Evaluation for preop cheop/RT• Only 83-88% specific in separating T-T2 from T3-T4
LN specificity• 28% for 5mm LN
• 62% for 7mm
NextPrevious
12
CEA scanCEA scan
Coupled with standard CT
• Can predict preop respectability
NextPrevious
13
PET ScanPET ScanStagingRestaging
– 91% sensitivity, ~ 100% specificity for pelvic disease (CT: 52%, 80%)
– 95% sensitivity for liver disease (CT 74%)
NextPrevious
14
StagingStagingDukes’ classification
– Based on depth of invasion and LN• A: Limited to bowel wall
• B: Extrarectal tissues
• C: LN +
Modified Dukes’ (Astler-Coller system)– C1 and C2
NextPrevious
15
TNMTNMStage I: T1 (invade submucosa) A
T2 (invade muscul propria) B1Stage II: T3 (invade through musc propria B2
into subserosa or nonperit. Tissue)
T4 (perforate ves perit or B3 invade adjacent structure)
Stage III: N1 (1-3 pericolic/rectal) N2 (> 4) C
N3 (along vascular trunk)
Stage IV: M1
NextPrevious
16
Prognostic FactorsPrognostic FactorsAdjacent tissue or vascular invasionNodal status
• Micromets (<5mm) same as enlarged LN
• 4 LN vs >4
? Cellular pathologic factors• S-phase, ploidy
Liver mets• Normal LFTs: 18 month med S
• Elevated Bil: 6 wks med S
NextPrevious
17
Prognostic FactorsPrognostic FactorsCEA
• Weak prognostic factor
• Persistant CEA elevation = Residual dz
• May increase initially during adjuvant
Not prognostic factors• Age, Sex, Tumor size
NextPrevious
18
Rectal CaRectal CaSurgical TreatmentSurgical Treatment
Abdominal Perineal Resection (APR)• Permanent Colostomy
Sphincter Preservation
NextPrevious
19
APRAPRBased on:
• Rectal cancer spread via lymphatic pathways in proximal, lateral and distal direction
Decreases local recurrenceImprove survivalPermanent colostomy
NextPrevious
20
APRAPRCandidates
• Primary sphincter dysfunction
• Tumor invading anal canal
• High risk for local recurrence• Bulky disease
• Poorly differentiated involving lower 1/3
• Direct extension into adjacent organs
NextPrevious
21
Total Mesorectal Excision Total Mesorectal Excision (TME)(TME)
Tumor spread into adjacent mesorectum>2cm distal extension from the margin carries
poor prognosisDecreases local recurrenceImprove survivalStandard for mid and lower rectal cancersPreserves pelvic autonomic nerve function
22
Surgical Options for Surgical Options for Sphincter PreservationSphincter Preservation
NextPrevious
23
Local ExcisionLocal ExcisionLower 1/3 early rectal cancer (T1)< 4 cm in diameterMobile lesionInvolve < 1/4 of circumference of bowelModerate to well differentiated
• From 2 prospective Trials• T1 : Local excision alone
• T2 : Local excision + CT/RT
NextPrevious
24
Local Excision with RTLocal Excision with RTIndications
– T2– Lymphatic/vascular invasion– Poor histology– Positive margin– Fragmented resection
NextPrevious
25
Endocavitary RTEndocavitary RTSelection criteria
• Distal lesion
• No disease beyond bowel wall
• No major extension to anal canal
• T < 3x5 cm
Local failure• 5-20%
• Salvage radical surgery
NextPrevious
26
Low Anterior Resection Low Anterior Resection (LAR)(LAR)
1- Bowel divided at 5cm above rectal tumor
2- Ligation of superior hemorrhoidal artery
3- Total Mesorectal Excision (TME) for mid/lower rectal tumors
4- 11/2 - 2cm distal margin
5- Colo-Rectal anastomosis
NextPrevious
27
Colonic J-PouchColonic J-Pouch
For low rectal cancer
To prevent incontinence/urgency
NextPrevious
28
APR vs Sphincter Sparing Resections APR vs Sphincter Sparing Resections (SSR) in Mid-rectal cancers(SSR) in Mid-rectal cancers
5 Y S %
APR SSR
Mayo et al 69 72
Patel et al 56 64
Jones/Thomson 52 67
Williams/Johnston 62 74
• Local recurrence: APR 8%, SSR 11% (not significant)
29
ADJUVANT THERAPYADJUVANT THERAPY
NextPrevious
30
Rectal CancerRectal CancerIncidence of local failure after resection
– T1, T2N0: <10%– T3N0: 15-30%– T3N1: 35-50%– T3-T4N1: 60%
• No successful salvage procedure
NextPrevious
31
Pre-Operative RTPre-Operative RTImproves local control (Several studies)
– Improves OS (Only one study)
Downside– Overtreatment of T1, T2
• Use Transrectal US
– Treatment of patient with hepatic mets• Use spiral CT
NextPrevious
32
Locally Advanced Rectal CancerLocally Advanced Rectal Cancer
PreOp external RT + IntraOp RT• 67%5Y local control, 57% DFS
PreOp RT or Chemo/RT• 70-85% resectability and sphincter sparing surgery
NextPrevious
33
Locally Recurrent DiseaseLocally Recurrent DiseaseTreatment options depend on
– Local extent• Isolated suture line recurrence after LAR
– APR + Chemo/RT if no prior RT
• Local recurrence without prior RT
– PreOp chemo/RT, Surgery + IORT
• Poor long-term DFS even with complete resection
– Symptoms– Distant mets– Prior adjuvant therapy
NextPrevious
34
CEACEA43-89% Sensitivity, 70-90% specificityPreOp elevation predicts worse prognosis
– Not useful in determining the need for adjuvant
Elevation correlates with Dukes’ stagePersistent 1-month postOp elevation predicts
metsMonitor CEA q2-3 moths during chemoModest elevation
• Fatty liver infiltration, hepatitis, pneumonia, GE
35
Systemic ChemotherapySystemic Chemotherapy
NextPrevious
36
5-FU5-FU 5 days IVP regimen:
• Mucositis, diarrhea, neutropenia
Wkly IVP regimen:• Diarrhea
CI regimen/Capecitabine:• Hand-foot syndrome, mucositis
• Diarrhea or neutropenia
High dose regimen 24-48hrs• Altered MS, angina-like chest pain
NextPrevious
Oxaliplatin = IrinotecanOxaliplatin = Irinotecan
FOLFOXFOLFIRIXELOXXELIRI
• AVASTIN/ZALTRAP• ERBITUX/VECTIBIX• REGORAFENIB
37
NextPrevious
38
Regional TherapyRegional Therapy(Liver Mets)(Liver Mets)
HAI of FUDR via an implanted pump• Addition of dexamthazone reduces sclerosing
cholangitis and enhances RR
Chemoembolization• 3mg/ml Adria + 3mg/ml MC + 10mg/ml CDDP with
bovine collagen
• Postembolization syndrome (fever, RtUQ pain, N/V, lethargy, hematologic toxicity)
Resection